One of the main goals of researchers working on GSK‐3 is to modulate GSK‐3β activity in specific target organs (e.g., brain or lungs), given the involvement of this kinase in many neurological diseases, including mood disorders, tauopathies, Alzheimer's disease, Parkinson's disease, viral encephalitis, or in diseases of the respiratory tract due to viral infections such as COVID‐19. This evidence concerns the gene GSK3B and COVID-19.